NCT lookup

Inclusion Criteria:

* Histologically or cytologically confirmed EGFR mutation positive NSCLC.
* Without any ongoing anti-cancer therapy or with stable ongoing anti-cancer therapy.
* At least one lesion that is present on 18F-FDG PET/CT scan during screening.
* ECOG performance status of 0 or 1.
* Anticipated life expectancy ≥ 12 weeks, in the opinion of the Investigator.
* Able to provide tumour tissue for analysis.

Exclusion Criteria:

* Confirmed radiographic disease progression or Investigator-assessed clinical disease progression within 28 days prior to the administration of \[111In\]-FPI-2107.
* Contraindications to or inability to perform the imaging procedures required in this study.
* Uncontrolled pleural effusion, pericardial effusion, or ascites requiring recurrent drainage procedures (≥ once per month).
* History of myocardial infarction or New York Heart Association Class II-IV congestive heart failure within 6 months of the administration of \[111In\]-FPI-2107, CTCAE Grade 2 or worse conduction defect or uncontrolled hypertension.
* Clinically relevant proteinuria, or daily urinary protein excretion \> 500 mg).
* Any antibody-based therapy targeting EGFR and/or c-MET, or investigational agent within 28 days or 5 half-lives prior to the administration of \[111In\]-FPI-2107, whichever is shorter.
* Any systemic radiopharmaceutical within 28 days or 5 radioactive half-lives prior to the administration of \[111In\]-FPI-2107, whichever is shorter.
* Any anticipated need for switching of any concomitant anti-cancer therapy during the imaging period of the study.
* External beam radiation therapy within 28 days prior to the administration of \[111In\]-FPI-2107.

• Beijing, China
• Shandong, China
• Wuhan, China